A shot in the Dark (Ages): a faint galaxy at z=9.76z=9.76 confirmed with JWST

The appearance of galaxies over the first billion years after the Big Bang is believed to be responsible for the last dramatic change in the state of the Universe. Ultraviolet photons from galaxies within this time period - the Epoch of Reionization - ionized intergalactic Hydrogen, rendering the Universe transparent to UV radiation and ending the so-called cosmic Dark Ages, sometime after redshift $z\sim8$. The majority of ionizing photons in the first few hundred Myrs of cosmic history are thought to derive from galaxies significantly fainter than the characteristic luminosity $L^{*}$. These faint galaxies are thought to be surrounded by sufficient neutral gas to prevent the escape of the Lyman-$\alpha$ photons that would allow confirmation with current observatories. Here we demonstrate the power of the recently commissioned James Webb Space Telescope to transform our understanding of the sources of reionization, by reporting the first spectroscopic confirmation of a very low luminosity ($\sim0.05 L^{*}$) galaxy at $z=9.76$, observed 480 Myr after the Big Bang, via the detection of the Lyman-break and redward continuum with the NIRSpec and NIRCam instruments. The galaxy JD1 is gravitationally magnified by a factor of $\mu\sim13$ by the foreground cluster A2744. The power of JWST and lensing allows us to peer deeper than ever before into the cosmic Dark Ages, revealing the compact ($\sim$150 pc) and complex morphology and physical properties of an ultrafaint galaxy ($M_{\rm UV}=-17.45$).Comment: Submitted to Nature. 34 pages, 4 main figures, 1 supplementary figure, 2 supplementary tables. Comments are welcom

Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis

Background. Pancreatic enzyme replacement therapy is the standard of care for treatment of malabsorption in patients with cystic fibrosis (CF) and exocrine pancreatic insufficiency (PI). Aim. To evaluate efficacy and safety of a new formulation of pancrelipase (Ultrase MT20) in patients with CF and PI. Coefficients of fat absorption (CFA%) and nitrogen absorption (CNA%) were the main efficacy parameters. Safety was evaluated by monitoring laboratory analyses, adverse events (AEs), and overall signs and symptoms. Methods. Patients (n=31) were randomized in a crossover design comparing this pancrelipase with placebo during 2 inpatient evaluation periods (6-7 days each). Fat and protein/nitrogen ingestion and excretion were measured from food diaries and 72-hour stool collections. CFA% and CNA% were calculated for each period and compared. Results. Twenty-four patients provided analyzable data. This pancrelipase increased mean CFA% and CNA% (+34.7% and +25.7%, resp., P<.0001 for both), reduced stool frequency, and improved stool consistency compared with placebo. Placebo-treated patients reported more AEs, with gastrointestinal symptoms being the most frequently reported AE. Conclusions. This pancrelipase is a safe and effective treatment for malabsorption associated with exocrine PI in patients with CF